Dr. Frederick R. Appelbaum is a world expert in the research and treatment of blood cancers. Prior to his appointment as executive vice president and deputy director of Fred Hutchinson Cancer Research Center in September 2013, for two decades he served as senior vice president and director of the Clinical Research Division at the Hutch.
As deputy director Appelbaum leads Fred Hutch’s strategic research partnerships with the National Institutes of Health and other federal agencies. He also represents the institution to the world at large, developing community relationships and programs needed to sustain the Hutch’s continued growth and impact.
At the Hutch, Appelbaum led the trials that defined the role of transplantation in the treatment of acute myeloid leukemia, myelodysplasia and malignant lymphoma. He continues to study the biology of AML and mechanisms of drug resistance.
Beyond his own research, Appelbaum has been a national leader in the conduct of clinical trials. In 1980, as part of SWOG Cancer Research Network, he formed the first multicenter bone marrow transplant clinical trials group. This concept eventually evolved into the federally funded Bone Marrow Transplant Clinical Trials Network, which he has chaired. For more than 20 years Appelbaum served as chair of the SWOG Leukemia Committee, which designs and conducts clinical trials for leukemia.
Appelbaum is past chair of the NCI Board of Scientific Advisors and has served on the boards of a number of scientific societies. He has also served on the NCI Leukemia Steering Committee and on the advisory committees of many organizations.
He holds the Metcalfe Family/Frederick Appelbaum Endowed Chair in Cancer Research at Fred Hutch. Other honors and awards include election to the Institute of Medicine and Alpha Omega Alpha medical honor society, the ASCO Statesman Award and the ASBMT’s E.D. Thomas Lecture and Award.